This week's happenings in the business world of psychedelic treatments
Psychedealia
 
Oregon’s Psilocybin Legalization Plan Under Scrutiny
Oregon is on the verge of deciding rules and regulations for legalizing medicinal psilocybin. The state’s voters approved legalization in November 2020 through Measure 109, with an operational program to be scheduled by early 2023, a move which instantly brought a huge international spotlight on the state...
 
 
Illegality Can’t Stop Popularity of Psychedelic Edibles From Growing
Magic mushrooms are legal in Brazil, Jamaica and the Netherlands, while some other countries have decriminalized psilocybin or only consider the mushrooms illegal in their dried form...
 
 
MindMed Raises $30 Million, Stock Plummets
Mind Medicine Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED) has priced its underwritten public offering of 7,058,823 common shares at $4.25. The shares come with warrants and the price includes both...
 
 
Oregon’s Silo Wellness Buys Dyscovry Science To Aid Psychedelic Retreats
Silo Wellness (CSE: SILO) (OTCQB: SILFF) is acquiring 100% of Dyscovry Science Ltd. in exchange for 49% of the issued outstanding securities of Silo and a chair on its board...
 
 
Tryp Looks at Patent for Psilocybin to Treat Fibromyalgia
Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patent applications. One patent application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other application, #63/375,305, expands the IP related to the company’s development of TRP-8803...
 
 
Psychedelics Provide Similar Benefits To Near-Death Experience – Without The Death
Trying psychedelic therapeutics can be a profound life-changing experience. Most participants in clinical trials report immediate relief from the issues that brought them to try psychedelics in the first place, whether it is understanding what causes their depression, how to deal with PTSD or just coming to terms with the demons deep within their consciousness...
 
 
 
In Other News
 
Reunion Neuroscience Appoints Greg Mayes as President and CEO
As Reunion’s new president and CEO, Greg Mayes’ initial focus will be on completing the company’s Phase 1 clinical trial with its lead asset and the planned launch of its
Phase 2 study in postpartum depression, which is expected to commence in 2023. Read more here.
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
Under the terms of the Agreement, Cybin will license intellectual property related to preclinical compounds within Mindset’s “Family 1” portfolio, excluding MSP-1014,
Mindset’s lead psychedelic drug candidate. Read more here.
Atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative
atai Life Sciences N.V. (Nasdaq: ATAI), which is an MDMA derivative for the treatment of post-traumatic stress disorder (PTSD) and other indications, announced today its Phase 1 study has received regulatory and ethics approvals required from Medsafe and HDEC, respectively, to initiate participant enrollment. Read more here.
 
 
 
 
Events
 
Oct. 11 Cantor/Wellness: Mental Health Clinics Symposium
Oct. 12-16 Horizons Perspectives on Psychedelics, NYC
Nov. 3-5 Wonderland, Miami FL
 
 
Facebook Twitter Instagram YouTube RSS
Green Market Report © 2017 – 2022. All rights reserved.
Unsubscribe      Subscribe      Advertise
 
Back to Top